Skip to main content
. 2017 Sep 1;6:e23708. doi: 10.7554/eLife.23708

Figure 1. P. falciparum and P. vivax molFOB (A), prevalence by qPCR (B) and LM (C) by week of follow-up.

Blue lines, P. falciparum; red lines, P. vivax; solid lines, placebo arm; dashed lines, PQ arm. Open circles in (B) mark enrolment qPCR prevalence for each species.

Figure 1.

Figure 1—figure supplement 1. Definition of new infections for calculating molFOB.

Figure 1—figure supplement 1.

Definition of P. falciparum new infections in two exemplary children is shown. The study design and timelines of follow-up are shown in upper panel: enrolment visit (‘E’), followed by radical treatment (black bar ‘T’) and 235 days of follow-up. The presence of P. falciparum clones by sampling visit is visualized below. Columns represent sampling visits, rows represent P. falciparum msp2 alleles, that is distinct P. falciparum clones. Grey solid circles, P. falciparum negative sample, grey open circle, missing sample due to missed follow-up visit; red circle: sample positive for respective Pf-msp2 allele. New infections were defined as a positive sample preceded by two samples negative for this allele (black rectangles), excluding missed samples (see Child 2, allele F, days 120–200). The time point of new infections is marked by arrows for the two children.
Figure 1—figure supplement 2. P. ovale and P. malariae prevalence by qPCR during follow-up.

Figure 1—figure supplement 2.

Purple lines, P. ovale; green lines, P. malariae; solid lines, Placebo arm; dashed lines, PQ arm. Open circles mark enrolment qPCR prevalence for each species.